vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $151.7M, roughly 1.2× Nutex Health, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 7.8%, a 40.1% gap on every dollar of revenue. On growth, BRC Group Holdings, Inc. posted the faster year-over-year revenue change (-21.9% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs -15.4%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
NUTX vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $188.3M |
| Net Profit | $11.8M | $90.3M |
| Gross Margin | 30.4% | 79.5% |
| Operating Margin | 20.4% | 32.3% |
| Net Margin | 7.8% | 47.9% |
| Revenue YoY | -41.1% | -21.9% |
| Net Profit YoY | -80.8% | 1710.8% |
| EPS (diluted) | $2.34 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.7M | $188.3M | ||
| Q3 25 | $267.8M | $215.3M | ||
| Q2 25 | $244.0M | $188.2M | ||
| Q1 25 | $211.8M | $197.2M | ||
| Q4 24 | $257.6M | $241.0M | ||
| Q3 24 | $78.8M | $225.5M | ||
| Q2 24 | $76.1M | $256.0M | ||
| Q1 24 | $67.5M | $263.4M |
| Q4 25 | $11.8M | $90.3M | ||
| Q3 25 | $55.4M | $91.1M | ||
| Q2 25 | $-17.7M | $139.5M | ||
| Q1 25 | $21.2M | $-10.0M | ||
| Q4 24 | $61.6M | $-5.6M | ||
| Q3 24 | $-8.8M | $-284.4M | ||
| Q2 24 | $-364.0K | $-433.6M | ||
| Q1 24 | $-364.0K | $-49.2M |
| Q4 25 | 30.4% | 79.5% | ||
| Q3 25 | 57.8% | 83.7% | ||
| Q2 25 | 51.2% | 81.3% | ||
| Q1 25 | 55.9% | 81.4% | ||
| Q4 24 | 55.0% | 79.8% | ||
| Q3 24 | 27.8% | 82.1% | ||
| Q2 24 | 29.7% | 84.5% | ||
| Q1 24 | 15.1% | 85.3% |
| Q4 25 | 20.4% | 32.3% | ||
| Q3 25 | 48.7% | 30.4% | ||
| Q2 25 | 13.8% | 5.7% | ||
| Q1 25 | 38.1% | -31.2% | ||
| Q4 24 | 44.4% | -69.2% | ||
| Q3 24 | 12.3% | -36.4% | ||
| Q2 24 | 7.0% | -90.8% | ||
| Q1 24 | 2.1% | -6.1% |
| Q4 25 | 7.8% | 47.9% | ||
| Q3 25 | 20.7% | 42.3% | ||
| Q2 25 | -7.3% | 74.1% | ||
| Q1 25 | 10.0% | -5.1% | ||
| Q4 24 | 23.9% | -2.3% | ||
| Q3 24 | -11.2% | -126.1% | ||
| Q2 24 | -0.5% | -169.4% | ||
| Q1 24 | -0.5% | -18.7% |
| Q4 25 | $2.34 | $2.78 | ||
| Q3 25 | $7.76 | $2.91 | ||
| Q2 25 | $-2.95 | $4.50 | ||
| Q1 25 | $3.33 | $-0.39 | ||
| Q4 24 | $11.56 | $-0.01 | ||
| Q3 24 | $-1.72 | $-9.39 | ||
| Q2 24 | $-0.07 | $-14.35 | ||
| Q1 24 | $-0.08 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $329.4M | $-171.5M |
| Total Assets | $918.5M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $185.6M | $226.6M | ||
| Q3 25 | $166.0M | $184.2M | ||
| Q2 25 | $96.7M | $267.4M | ||
| Q1 25 | $84.7M | $138.3M | ||
| Q4 24 | $40.6M | $146.9M | ||
| Q3 24 | $46.9M | $159.2M | ||
| Q2 24 | $40.8M | $236.9M | ||
| Q1 24 | $30.0M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $329.4M | $-171.5M | ||
| Q3 25 | $317.2M | $-260.5M | ||
| Q2 25 | $235.3M | $-351.7M | ||
| Q1 25 | $176.9M | $-496.8M | ||
| Q4 24 | $132.4M | $-488.2M | ||
| Q3 24 | $60.4M | $-497.6M | ||
| Q2 24 | $62.7M | $-218.3M | ||
| Q1 24 | $63.0M | $228.4M |
| Q4 25 | $918.5M | $1.7B | ||
| Q3 25 | $964.5M | $1.7B | ||
| Q2 25 | $841.0M | $1.5B | ||
| Q1 25 | $761.9M | $1.5B | ||
| Q4 24 | $655.3M | $1.8B | ||
| Q3 24 | $438.5M | $2.2B | ||
| Q2 24 | $422.4M | $3.2B | ||
| Q1 24 | $404.3M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | $26.2M |
| Free Cash FlowOCF − Capex | $69.0M | — |
| FCF MarginFCF / Revenue | 45.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | 5.95× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.4M | $26.2M | ||
| Q3 25 | $99.5M | $-60.6M | ||
| Q2 25 | $27.3M | $-25.6M | ||
| Q1 25 | $51.0M | $184.0K | ||
| Q4 24 | $54.0K | $-2.7M | ||
| Q3 24 | $6.8M | $19.5M | ||
| Q2 24 | $13.3M | $111.5M | ||
| Q1 24 | $3.1M | $135.4M |
| Q4 25 | $69.0M | — | ||
| Q3 25 | $99.2M | — | ||
| Q2 25 | $26.5M | — | ||
| Q1 25 | $50.9M | — | ||
| Q4 24 | $-341.0K | — | ||
| Q3 24 | $6.2M | — | ||
| Q2 24 | $12.7M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 45.5% | — | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 24.0% | — | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 16.7% | — | ||
| Q1 24 | 3.4% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 5.95× | 0.29× | ||
| Q3 25 | 1.80× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
